IS2254B - Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni - Google Patents

Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni

Info

Publication number
IS2254B
IS2254B IS5570A IS5570A IS2254B IS 2254 B IS2254 B IS 2254B IS 5570 A IS5570 A IS 5570A IS 5570 A IS5570 A IS 5570A IS 2254 B IS2254 B IS 2254B
Authority
IS
Iceland
Prior art keywords
adenocytes
giant
treatment
lupus erythematosus
treat
Prior art date
Application number
IS5570A
Other languages
English (en)
Other versions
IS5570A (is
Inventor
Browning Jeffrey
Thorbecke Jeanette
Tsiagbe Vincent
Original Assignee
Biogen Idec Ma Inc.
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc., New York University filed Critical Biogen Idec Ma Inc.
Publication of IS5570A publication Critical patent/IS5570A/is
Publication of IS2254B publication Critical patent/IS2254B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5570A 1998-01-30 2000-07-21 Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni IS2254B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (2)

Publication Number Publication Date
IS5570A IS5570A (is) 2000-07-21
IS2254B true IS2254B (is) 2007-06-15

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5570A IS2254B (is) 1998-01-30 2000-07-21 Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni

Country Status (25)

Country Link
EP (1) EP1051187B9 (is)
JP (2) JP4713733B2 (is)
KR (1) KR100622960B1 (is)
CN (1) CN1287853C (is)
AT (1) ATE253930T1 (is)
AU (1) AU752710B2 (is)
BR (1) BR9908214A (is)
CA (1) CA2319698A1 (is)
CZ (1) CZ301026B6 (is)
DE (1) DE69912743T2 (is)
DK (1) DK1051187T3 (is)
EA (1) EA003862B1 (is)
EE (1) EE05235B1 (is)
ES (1) ES2211035T3 (is)
HK (1) HK1029944A1 (is)
HU (1) HU226044B1 (is)
IL (2) IL137489A0 (is)
IS (1) IS2254B (is)
NO (1) NO328116B1 (is)
NZ (1) NZ506529A (is)
PL (1) PL203279B1 (is)
PT (1) PT1051187E (is)
SK (1) SK285725B6 (is)
TR (2) TR200101693T2 (is)
WO (1) WO1999038525A1 (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0012006A (pt) * 1999-06-28 2002-03-12 Basf Ag Método para evitar inflamações, doenças autoimunes e crescimento de tumor, e, uso de substâncias que suprimem a ativação mediada por ltbr
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
CN1547590A (zh) 2000-10-13 2004-11-17 ¸ 人源化抗-LT-β-R抗体
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
ES2532607T3 (es) 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
TW200416044A (en) 2002-07-01 2004-09-01 Biogen Inc Humanized anti-lymphotoxin β receptor antibodies
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
US20060122132A1 (en) * 2002-08-14 2006-06-08 Touw Ivo P Use of murine genomic regions identified to be involved in tumor developement for the development of anti-cancer drugs and diagnosis of cancer
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
AU752710B2 (en) 2002-09-26
EA003862B1 (ru) 2003-10-30
EE05235B1 (et) 2009-12-15
EA200000798A1 (ru) 2001-02-26
NO20003848D0 (no) 2000-07-27
HU226044B1 (en) 2008-03-28
CN1287853C (zh) 2006-12-06
CZ20002751A3 (cs) 2000-12-13
DK1051187T3 (da) 2004-03-08
EE200000446A (et) 2001-08-15
BR9908214A (pt) 2000-11-28
JP4713733B2 (ja) 2011-06-29
CZ301026B6 (cs) 2009-10-14
PT1051187E (pt) 2004-03-31
SK285725B6 (sk) 2007-07-06
WO1999038525A1 (en) 1999-08-05
JP2002501902A (ja) 2002-01-22
EP1051187B9 (en) 2004-08-11
IS5570A (is) 2000-07-21
NZ506529A (en) 2002-12-20
HUP0102363A2 (hu) 2001-10-28
JP2010235621A (ja) 2010-10-21
NO328116B1 (no) 2009-12-14
DE69912743D1 (de) 2003-12-18
PL203279B1 (pl) 2009-09-30
AU2348899A (en) 1999-08-16
SK11302000A3 (sk) 2001-01-18
PL342063A1 (en) 2001-05-21
KR20010040497A (ko) 2001-05-15
IL137489A0 (en) 2001-07-24
DE69912743T2 (de) 2004-09-23
TR200101693T2 (tr) 2002-06-21
CA2319698A1 (en) 1999-08-05
EP1051187A1 (en) 2000-11-15
NO20003848L (no) 2000-10-02
TR200002203T2 (tr) 2000-12-21
EP1051187B1 (en) 2003-11-12
CN1289252A (zh) 2001-03-28
ES2211035T3 (es) 2004-07-01
IL137489A (en) 2010-05-31
ATE253930T1 (de) 2003-11-15
KR100622960B1 (ko) 2006-09-12
HUP0102363A3 (en) 2004-04-28
HK1029944A1 (en) 2001-04-20

Similar Documents

Publication Publication Date Title
ES2153337T1 (es) Inhibidores de raf-quinasa.
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
EA199800667A1 (ru) Новые фенантридины
MY169308A (en) Treatment of tnf? related disorders
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
ATE297922T1 (de) Isoindolin-1-on als glukokinaseaktivatoren
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ATE461217T1 (de) Glp-1-verbindungen
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
EA200000351A1 (ru) Лечение кондуктивных нарушений
IS5570A (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
EA200400235A1 (ru) Комбинированная терапия для лечения рака
DE69914357D1 (de) Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
DK1223930T3 (da) Behandling af dyskinesi
NO20005548D0 (no) Mykobakterieinhibitorer
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
MY140194A (en) Novel fusidic acid derivatives
EA200200321A1 (ru) Апоптин-ассоциированный белок
AU2013204147B2 (en) Treatment of TNFalpha related disorders